Surrogate and Composite Endpoints in Pharmaceutical Clinical Trials


This training will review the regulatory definitions and correct implementation of composite and surrogate endpoints in pharmaceutical clinical trials. The program will compare these endpoints with traditional (direct) endpoints, summarizing the major advantages and challenges associated with them.

Visitors

CRAs and CRCs,Biostatisticians,Clinical trial QA,Documentation professionals

Exhibitors

Carolynn E Pietrangeli PhD., is an academic Immunologist with over two decades of experience working with the pharmaceutical industry, Dr. Pietrangeli has extensive experience with clinical trial planning, preparation of materials for the FDA and the education of industry personnel responsible for the execution of clinical trials. Therapeutic areas include solid organ and stem cell transplantation, hepatitis, HIV/AIDS, Alzheimer's disease, dermatology and autoimmune diseases.

Go to event website